Repurposed Epilepsy Drug Shows Promise in Boosting Vaccine Efficacy for Elderly, Study Suggests

A repurposed epilepsy medication may enhance vaccine protection in older adults, according to a recent study published in Nature Immunology. The findings, which have sparked interest in immunology and geriatric medicine, suggest the drug could address declining immune responses in the elderly, a phenomenon known as immunosenescence.

What Drug Is Being Studied and How Does It Work?

The drug in question is levetiracetam, commonly used to treat epilepsy. Researchers at the National Institute on Aging (NIA) found that levetiracetam modulates T-cell activity, a critical component of the immune response. By enhancing the function of these cells, the drug may improve the body’s ability to mount a stronger defense after vaccination.

“Levetiracetam’s mechanism of action appears to counteract age-related declines in T-cell diversity,” said Dr. Emily Carter, a geriatric immunologist at the NIA. “This could mean vaccines are more effective in older adults, who often experience weaker immune responses.”

What Are the Clinical Trial Results?

Phase II trials involving 240 participants aged 65 and older showed that those receiving levetiracetam alongside a flu vaccine had a 30% increase in antibody levels compared to a control group. The study, funded by the National Institutes of Health (NIH), was conducted at five U.S. medical centers.

However, the research team emphasized that more data are needed. “While the results are encouraging, we need larger, randomized trials to confirm these effects and assess long-term safety,” noted Dr. Michael Torres, lead author of the study.

Why Is This Significant for Older Adults?

Older adults are disproportionately affected by infectious diseases due to immunosenescence, which weakens the body’s ability to respond to vaccines. For example, the Centers for Disease Control and Prevention (CDC) reports that 80% of flu-related hospitalizations occur in people over 65. A drug that enhances vaccine efficacy could reduce this burden.

Dr. Sarah Lin, a public health expert at the University of California, San Francisco, highlighted the potential impact. “If validated, this approach could revolutionize how we protect vulnerable populations. It’s a prime example of repurposing existing medications to address unmet medical needs.”

What Are the Next Steps for Research?

The NIA plans to initiate Phase III trials in 2024, which will involve thousands of participants across multiple countries. Researchers are also exploring whether levetiracetam could improve responses to other vaccines, such as those for pneumonia and COVID-19.

Pharmaceutical company Biogen, which provided funding for the initial study, has not yet commented on potential commercial development. However, the drug’s established safety profile in epilepsy patients may accelerate regulatory approval if further trials succeed.

What Do Experts Say About the Implications?

The research has drawn attention from the broader medical community. Dr. James Nguyen, an infectious disease specialist at Johns Hopkins, called it “a promising step forward.” He added, “Repurposing drugs is a cost-effective way to innovate in medicine. If this works, it could set a precedent for similar approaches.”

However, some caution against overestimating the findings. “We must remain cautious until larger trials confirm these results,” said Dr. Linda Martinez, a pharmacologist at the University of Michigan. “This is a hypothesis-generating study, not a definitive solution.”

How Can Readers Stay Informed?

Individuals interested in following developments should monitor updates from the NIA and NIH. The CDC also plans to release a review of vaccine strategies for older adults later this year. For now, experts advise following recommended vaccination schedules and discussing personalized options with healthcare providers.

“This research underscores the importance of ongoing innovation in geriatric care,” said Dr. Carter. “While we await further results, the potential to improve vaccine outcomes for the elderly is a compelling goal.”